Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
In a trial combining Keytruda with Oncologie’s investigational drug that targets phosphatidylserine, the response rate was 43% among patients with a low... Read More
Foundation-Funded Lab at MD Anderson Advances Discoveries in Peritoneal Carcinomatosis
About 45% of gastric cancer patients experience peritoneal carcinomatosis (PC), the spread of the cancer to the abdominal lining—a development that’s associated... Read More
Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
CARsgen Therapeutics was granted orphan drug designation by the US FDA for CAR-T Cells for the treatment of gastric and gastroesophageal junction... Read More
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction cancer, with... Read More
New Grant Awarded to USC for Study of Epigenetic Targets in Gastric Cancer
Some gastric tumors have genetic abnormalities that can be directly targeted with drugs, such as HER2 mutations. But cancer is a complex... Read More
New Foundation Grant to Dana-Farber for Study of “Chromosomal Instability” in Gastric Cancer
Gastric tumors with a genetic abnormality called microsatellite instability-high (MSI-H) can be treated with immune-targeted drugs, but there’s a much more common... Read More
Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
Basilea Pharmaceutica has started a study of a drug that inhibits the cancer-driving protein FGFR. It will be studied alone and with... Read More
Association of malnutrition with geriatric assessment impairments and health‐related quality of life among older adults with gastrointestinal malignancies
Gastric cancer patients over age 60 face a high risk of malnutrition, which lowers their quality of life and leads to a... Read More
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
The FDA granted fast-track designation to Leap Therapeutics’ DKN-01, which blocks the DKK1 protein found in abundance in some gastric tumors.